Current financial headlines
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
Chronological news
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped …
Sharemaestro market context Price above Trend Line 52 weeks -21.9%Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The …
Sharemaestro market context Trend signal active 52 weeks +40.9% · Next-week setup negative 44.7%Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Sen. Elizabeth Warren (D-Mass) has criticized the vertical integration in the U.S. healthcare system, arguing that it leads to higher costs for patients and increased profits for …
Sharemaestro market context Trend signal active 52 weeks +26.7%For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and …
Sharemaestro market context Trend signal active 52 weeks +61.5%Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly › Eli …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. argenx (ENXTBR:ARGX) is set to consider and discuss the acquisition of Forte Biosciences, Inc. The potential deal would expand argenx's reach in biopharmaceutical …
Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items. …
In the latest close session, Medtronic (MDT) was up +2.58% at $89.41. The stock outperformed the S&P 500, which registered a daily loss of 0.06%. Elsewhere, the Dow lost 0.11%, while the tech-heavy Nasdaq lost 0.32%. The medical device company's stock has climbed by …
The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one …
Sharemaestro market context Trend signal active 52 weeks +61.5%Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Broker Signals On Veeva Systems Stock A fresh wave of brokerage opinions on Veeva Systems (VEEV) has put the stock back in focus for investors, …
Intuitive Surgical (NASDAQ:ISRG) beat both top- and bottom-line consensus estimates in its fiscal Q2 2026 results, with revenue for the quarter growing 19% to $2.89 billion and adjusted EPS of $2.80 exceeding expectations by $0.30. Despite that, the stock plunged due to mounting concerns …
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised …
Sharemaestro market context Trend signal active 52 weeks +40.9% · Next-week setup negative 44.7%Orchestra BioMed Holdings, Inc. The BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints …
Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~€2B, and …
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for Silver Upgrade …
Sharemaestro market context Trend signal active 52 weeks +61.5%This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and …
In late July 2026, Thermo Fisher Scientific used the ADLM conference in Anaheim to highlight new FDA-cleared diagnostic platforms, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, alongside expanded digital and quality-control offerings for …
LOUISVILLE, Ky., August 10, 2026--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced that James "J.P." Holland will join the company as senior vice president and President of Medicaid, effective August 17. In this role, Holland will lead the company's growing Medicaid business, which currently serves …
During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors …
Sharemaestro market context Trend signal active 52 weeks +61.5%S&P 500 companies' quarterly earnings growth rate eased from a week ago amid a drop in the healthcar PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. …
Sharemaestro market context Trend signal active 52 weeks +46.5%Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corporation (NYSE:BSX), purchased 186,240 shares of common stock at $48.34 per share on August 3, 2026. SEC Form 4 filing. Transaction summary Metric Value Transaction value $10.1 million Shares purchased 208,359 Post-transaction shares (total) …
Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …
Sharemaestro market context Trend signal active 52 weeks +61.5%QuidelOrtho Corporation QDEL delivered adjusted earnings per share (EPS) of 13 cents in second-quarter 2026, up 8.3% year over year. The figure beat the Zacks Consensus Estimate by 425%. The adjustments include expenses related to the amortization of intangibles, acquisition and integration costs, among …
Sharemaestro market context Price above Trend Line 52 weeks +15.8%Integer Holdings Corporation ITGR delivered adjusted earnings per share (EPS) of $1.60 in the second quarter of 2026, up 3.2% year over year. The figure beat the Zacks Consensus Estimate by 15.9%. The adjustments include expenses related to the amortization of intangible assets and …
Sharemaestro market context Price above Trend Line 52 weeks +15.8%AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face …
Inogen, Inc. INGN reported breakeven earnings for second-quarter 2026, compared to the year-ago period's adjusted loss of 2 cents per share. GAAP loss per share of 14 cents, narrower than the year-ago loss of 15 cents. The figure beat the Zacks Consensus Estimate by …
iRhythm Holdings, Inc. IRTC reported adjusted earnings per share of 58 cents in the second quarter of 2026, against an adjusted loss per share of 32 cents a year ago. The figure beat the Zacks Consensus Estimate by 5900%. GAAP loss per share for …
Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while …
This article first appeared on GuruFocus. Vertex Pharmaceuticals (NASDAQ:VRTX), the biotech king of cystic fibrosis, jumped approximately 5.9% in Monday's regular session after a rival drug stumbled. Sionna Therapeutics said SION-719 missed the key activity endpoint in a Phase 2a trial when added to …
Immunocore Holdings plc IMCR offers a clear trade-off between commercial momentum and valuation risk. Kimmtrak continues to expand in metastatic uveal melanoma, while late-stage studies could open larger markets. The counterweight is equally clear. IMCR relies on one marketed product, trades above key industry …
Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Everyone has their own methods …
Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consensus estimate of a loss of …
The European stock markets closed mixed in Monday trading as investors continue to gauge development PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …
On this episode of Stock Movers:- RocketLab (RKLB) shares are higher this morning after rising Friday, following earnings from SpaceX last week.- Moderna (MRNA) shares are moving after last week's news that its mRNA flu shot won US approval in an FDA turnaround.- Intel …
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. …
Sharemaestro market context Trend signal active 52 weeks +46.5%Search by ticker symbol or company name and select a result to open its chart.